Myelin Repair and Neuroprotection in Multiple Sclerosis

Myelin Repair and Neuroprotection in Multiple Sclerosis presents an up-date on the translational potential of promoting remyelination in multiple sclerosis (MS). A number of research frontiers still exist in this challenging disease. The cause remains elusive, preventing breakthroughs in its prevention. The move towards oral immunomodulatory therapies has been a major advance, as has the finding of new genes linked to susceptibility that may open the door to new therapeutic approaches. However, a frontier that has been making significant strides in recent years has been that surrounding the neurobiology of myelin regeneration and axon protection: such have been the advances that clinical translation is on the cusp of being achieved. Two broad approaches to therapeutic enhancement of remyelination are envisaged: promoting endogenous remyelination by targeting cells present in the CNS, or, replacing lost myelinating cells from exogenous sources. Current research on oligodendrocyte biology, the pathology of MS, imaging of lesions and the biology of remyelination are paving the way toward opening this new translational frontier.

Professor Duncan and Professor Franklin have assembled a broad group of experts in the fields of glial cell biology, neuropathology, radiology and clinical neurology to provide the background toward taking remyelination from experimented models into MS patients.

First book on this topic Authorship from many of the major players in the field of MS and myelin repair Of equal interest to academic clinical neurologists and neuroscientists Includes supplementary material: sn.pub/extras

Klappentext

Myelin Repair and Neuroprotection in Multiple Sclerosis presents an up-date on the translational potential of promoting remyelination in multiple sclerosis (MS). A number of research frontiers still exist in this challenging disease. The cause remains elusive, preventing breakthroughs in its prevention. The move towards oral immunomodulatory therapies has been a major advance, as has the finding of new genes linked to susceptibility that may open the door to new therapeutic approaches. However, a frontier that has been making significant strides in recent years has been that surrounding the neurobiology of myelin regeneration and axon protection: such have been the advances that clinical translation is on the cusp of being achieved. Two broad approaches to therapeutic enhancement of remyelination are envisaged: promoting endogenous remyelination by targeting cells present in the CNS, or, replacing lost myelinating cells from exogenous sources. Current research on oligodendrocyte biology, the pathology of MS, imaging of lesions and the biology of remyelination are paving the way toward opening this new translational frontier.

Professor Duncan and Professor Franklin have assembled a broad group of experts in the fields of glial cell biology, neuropathology, radiology and clinical neurology to provide the background toward taking remyelination from experimented models into MS patients.

Inhalt
Development of oligodendrocytes in the vertebrate CNS.- Demyelination and remyelination in multiple sclerosis.- Microglia function in MS pathology.- Endogenous remyelination in the CNS.- Exogenous cell myelin repair and neuroprotection in multiple sclerosis.- A peripheral alternative to central nervous system myelin repair.- Immune modulation and repair following neural stem transplantation.- Axonal protection with sodium channel blocking agents in models of multiple sclerosis.- Effects of current medical therapies on reparative and neuroprotective functions in multiple sclerosis.- Imaging of demyelination and remyelination in multiple sclerosis.- Designing clinical trials to test neuroprotective therapies in multiple sclerosis..